Capitol Hill lawmakers and the Trump administration have been ramping up the scrutiny of Chinese biotechs as U.S. companies increasingly turn to China as a source of biopharma innovation. Last year, Trump’s “America First Investment Policy” branded China as a main rival and biotechnology as a sector requiring more regulation. Since then, adding biotechnology to the implementation of the Comprehensive Outbound Investment National Security (COINS) Act has become a mission for certain members of Congress and—more recently—the Senate. The ultimate aim is to restrict or even block the burgeoning licensing deals between the two countries in the name of protecting U.S. leadership in biotech innovation and national security. But so far, the market is telling a different story.

Full report : Chinese biotechs told Fierce they aren’t losing sleep over the ramping up of rhetoric coming out of the U.S.